These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 24636833)

  • 21. A 96-week randomized trial of switching to entecavir in patients who achieved virological suppression on lamivudine therapy.
    Ahn SH; Heo J; Park JY; Woo HY; Lee HJ; Tak WY; Um SH; Yoon KT; Park SY; Kim CW; Kim HH; Han KH; Cho M
    J Gastroenterol Hepatol; 2016 Apr; 31(4):865-71. PubMed ID: 26572068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
    Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
    J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Five-year results of oral antiviral therapy in HBeAg-negative chronic Hepatitis B.
    Atay K; Hatemi İ; Canbakan B; Köroğlu E; Durcan E; Yurttaş B; Gültepe İ; Özdemir S; Tuncer M; Sonsuz A
    Turk J Gastroenterol; 2016 May; 27(3):279-83. PubMed ID: 27210786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Evolution of hepatitis B virus quasispecies during lamivudine-entecavir sequential therapy].
    Liu L; Tang YZ; Li JG; Zhou JJ; Wang XH; Wang YM
    Zhonghua Gan Zang Bing Za Zhi; 2010 Jun; 18(6):423-7. PubMed ID: 20587311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the efficacy of Lamivudine plus adefovir versus entecavir in the treatment of Lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis.
    Huang ZB; Zhao SS; Huang Y; Dai XH; Zhou RR; Yi PP; Chen RC; Li WT; Zhang BX; Li N; Fan XG
    Clin Ther; 2013 Dec; 35(12):1997-2006. PubMed ID: 24238791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Entecavir plus adefovir combination therapy versus lamivudine add-on adefovir for lamivudine-resistant chronic hepatitis B: A meta-analysis.
    Zeng T; Xu H; Liu JY; Lei Y; Zhong S; Zhou Z
    J Clin Pharmacol; 2014 Sep; 54(9):959-67. PubMed ID: 24964070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
    Gish RG; Lok AS; Chang TT; de Man RA; Gadano A; Sollano J; Han KH; Chao YC; Lee SD; Harris M; Yang J; Colonno R; Brett-Smith H
    Gastroenterology; 2007 Nov; 133(5):1437-44. PubMed ID: 17983800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Week 24 suppression of HBV in entecavir-treated chronic hepatitis B patients in whom lamivudine treatment failed is associated with efficacy at week 48].
    Ma H; Ren JB; Li HY; Wang Y; Wang RL; Liang L; Sun SJ; Jia JD
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Jun; 21(2):102-4. PubMed ID: 17653304
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
    Maklad S; Doss W; El Din SS; Hassan K; Zeid AA
    Arab J Gastroenterol; 2014 Mar; 15(1):1-5. PubMed ID: 24630505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.
    Reijnders JG; Deterding K; Petersen J; Zoulim F; Santantonio T; Buti M; van Bömmel F; Hansen BE; Wedemeyer H; Janssen HL;
    J Hepatol; 2010 Apr; 52(4):493-500. PubMed ID: 20185191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
    Chang TT; Chao YC; Gorbakov VV; Han KH; Gish RG; de Man R; Cheinquer H; Bessone F; Brett-Smith H; Tamez R
    J Viral Hepat; 2009 Nov; 16(11):784-9. PubMed ID: 19457141
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An evaluation of entecavir for the treatment of chronic hepatitis B infection in adults.
    Lee HW; Park JY; Ahn SH
    Expert Rev Gastroenterol Hepatol; 2016; 10(2):177-86. PubMed ID: 26610256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Entecavir versus lamivudine in the treatment of chronic hepatitis B patients with hepatic decompensation.
    Hsu YC; Mo LR; Chang CY; Perng DS; Tseng CH; Lo GH; Tai CM; Lin CW; Hsu CC; Hsu CY; Huang SC; Lin JT
    Antivir Ther; 2012; 17(4):605-12. PubMed ID: 22301517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Five years trial of entecavir for chronic hepatitis B patients failed with lamivudine therapy in the Chongqing area].
    LI H; WANG ZY; ZHANG DZ; SHI XF; ZHOU Z; REN H
    Zhonghua Gan Zang Bing Za Zhi; 2009 May; 17(5):338-41. PubMed ID: 19497197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.
    Leemans WF; Niesters HG; van der Eijk AA; Janssen HL; Schalm SW; de Man RA
    Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):773-7. PubMed ID: 18617782
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy.
    Reijnders JG; Pas SD; Schutten M; de Man RA; Janssen HL
    J Hepatol; 2009 Apr; 50(4):674-83. PubMed ID: 19231002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A study on the treatment of chronic hepatitis B with YMDD mutation].
    Qiu YW; Jiang XH; Huang LH; Hu TH; Ding H; Jiang YM; Dai YX; Zhou M
    Zhonghua Gan Zang Bing Za Zhi; 2009 Mar; 17(3):171-4. PubMed ID: 19335977
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term efficacy of entecavir therapy in chronic hepatitis B patients with antiviral resistance to lamivudine and adefovir.
    Kwak MS; Choi JW; Lee JS; Kim KA; Suh JH; Cho YS; Won SY; Park BK; Lee CK
    J Viral Hepat; 2011 Oct; 18(10):e432-8. PubMed ID: 21914060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels.
    Wong DK; Yuen MF; Ngai VW; Fung J; Lai CL
    Antivir Ther; 2006; 11(7):909-16. PubMed ID: 17302253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study.
    Liaw YF; Raptopoulou-Gigi M; Cheinquer H; Sarin SK; Tanwandee T; Leung N; Peng CY; Myers RP; Brown RS; Jeffers L; Tsai N; Bialkowska J; Tang S; Beebe S; Cooney E
    Hepatology; 2011 Jul; 54(1):91-100. PubMed ID: 21503940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.